Acute Coronary Syndrome

Summary

GlobalData, the industry analysis specialist's new report, Acute Coronary Syndrome - Drug Pipeline Analysis and Market Forecasts to 2016 is an essential source of information and analysis on the global acute coronary syndrome market. The report identifies the key trends shaping and driving the global acute coronary syndrome market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global acute coronary syndrome sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.

Scope

The scope of the report includes:

• Annualized global acute coronary syndrome market revenues data from 2001 to 2009, forecast forward for 7 years to 2016.
• Geographic markets covered in this report include the US (United States), the UK (United Kingdom), Italy, Spain, Germany, France, and Japan.
• Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends.
• Analysis of the current and future market competition in the global acute coronary syndrome market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with acute coronary syndrome

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

• Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global acute coronary syndrome market.
• Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global acute coronary syndrome market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What's the next big thing in the global acute coronary syndrome market landscape? - Identify, understand and capitalize.

Contents

• 1 Table of contents
  • 1.1 List of Tables
  • 1.2 List of Figures
• 2 Global Acute Coronary Syndrome: Market Characterization
  • 2.1 Overview
  • 2.2 Acute Coronary Syndrome Market Size
  • 2.3 Acute Coronary Syndrome Market Forecast and CAGR
  • 2.4 Drivers and Barriers for the Acute Coronary Syndrome Market
    • 2.4.1 Drivers for the Acute Coronary Syndrome Market
    • 2.4.2 Barriers for the Acute Coronary Syndrome Market
  • 2.5 Opportunity and Unmet Need
  • 2.6 Key Takeaway
• 3 Global Acute Coronary Syndrome Market: Competitive Assessment
  • 3.1 Overview
  • 3.2 Strategic Competitor Assessment
  • 3.3 Product Profile for the Major Marketed Products in the Acute Coronary Syndrome Market
    • 3.3.1 Lovenox (enoxaparin sodium injection)
    • 3.3.2 Angiomax (bivaluridin, Angiox)
    • 3.3.3 Integrilin (Eptifibatide)
    • 3.3.4 Aggrastat (tirofiban hydrochloride)
    • 3.3.5 Plavix (Clopidogrel bisulfate)
    • 3.3.6 Effient (prasugrel)
  • 3.4 Key Takeaway
• 4 Global Acute Coronary Syndome Market: Pipeline Assessment
  • 4.1 Overview
  • 4.2 Strategic Pipeline Assessment
  • 4.3 Acute Coronary Syndrome Market - Promising Drugs under Clinical Development
  • 4.4 Molecule Profile for Promising Drugs under Clinical Development
    • 4.4.1 Brilinta (ticagrelor)
    • 4.4.2 Apixaban (BMS-562247-01)
    • 4.4.3 Arixtra (fondaparinux)
    • 4.4.4 RO4607381/R1658
    • 4.4.5 MC-1
  • 4.5 Acute Coronary Syndrome Market - Clinical Pipeline by Mechanism of Action
    • 4.5.1 Acute Coronary Syndrome - Phase III Clinical Pipeline
    • 4.5.2 Acute Coronary Syndrome - Phase II Clinical Pipeline
    • 4.5.3 Acute Coronary Syndrome - Phase I Clinical Pipeline
    • 4.5.4 Acute Coronary Syndrome - Preclinical Pipeline
    • 4.5.5 Acute Coronary Syndrome - List of Terminated Clinical Trials
  • 4.6 Key Take Away
• 5 Global Acute Coronary Syndrome Market: Implications for Future Market Competition
• 6 Global Acute Coronary Syndrome Market: Future Players
  • 6.1 Introduction
  • 6.2 GlaxoSmithKline
    • 6.2.1 Company Overview
    • 6.2.2 Business Description
  • 6.3 Sanofi-Aventis
    • 6.3.1 Company Overview
    • 6.3.2 Business Description
  • 6.4 Bristol-Myers Squibb Company
    • 6.4.1 Company Overview
    • 6.4.2 Business Description
  • 6.5 AstraZeneca
    • 6.5.1 Overview
    • 6.5.2 Business Description
  • 6.6 Daiichi Sankyo Co.Ltd
    • 6.6.1 Company Overview
    • 6.6.2 Business Description
  • 6.7 Pfizer Inc
    • 6.7.1 Company Overview
    • 6.7.2 Business Description
• 7 Acute Coronary Syndrome Market: Appendix
  • 7.1 Definitions
  • 7.2 Acronyms
  • 7.3 Research Methodology
    • 7.3.1 Coverage
    • 7.3.2 Secondary Research
    • 7.3.3 Forecasting
    • 7.3.4 Primary Research
    • 7.3.5 Expert Panels
  • 7.4 Contact Us
  • 7.5 Disclaimer
  • 7.6 Sources
• List of Tables
  • Table 1: Acute Coronary Syndrome, Global, Historical Revenue ($m), 2001-2009
  • Table 2: Acute Coronary Syndrome, Global, Forecasted Reveune ($m), 2009-2016
  • Table 3: Major Marketed Products Comparison in Acute Coronary Syndrome Market, 2010
  • Table 4: Acute Coronary Syndrome - Most Promising Drugs Under Clinical Development, 2010
  • Table 5: Acute Coronary Syndrome Therapeutics - Phase III Clinical Pipeline, 2010
  • Table 6: Acute Coronary Syndrome Therapeutics - Phase II Clinical Pipeline, 2010
  • Table 7: Acute Coronary Syndrome - Phase I Clinical Pipeline, 2010
  • Table 8: Acute Coronary Syndrome - Preclinical Pipeline, 2010
  • Table 9: Acute Coronary Syndrome - List of Terminated Clinical Trials, 2010
  • Table 10: GlaxoSmithKline - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010
  • Table 11: Sanofi-Aventis - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010
  • Table 12: Bristol-Myers Squibb - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010
  • Table 13: AstraZeneca - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010
  • Table 14: Daiichi Sankyo - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010
  • Table 15: Pfizer Inc - Cardiovascular and Acute Coronary Syndrome Pipeline Product Portfolio, 2010
• List of Figures
  • Figure 1: Acute Coronary Syndrome, Global, Historical Revenue ($m), 2001-2009
  • Figure 2: Acute Coronary Syndrome, Global, Forecasted Revenue ($m), 2009-2016
  • Figure 3: Opportunity and Unmet Need in the Acute Coronary Syndrome Market, 2010
  • Figure 4: Strategic Competitor Assessment, 2010
  • Figure 5: Pipeline Products by Phase of Development, 2009
  • Figure 6: Technology Trends Analytics Frame Work, 2010
  • Figure 7: Technology Trends Analytics Frame Work - Description, 2010
  • Figure 8: Acute Coronary Syndrome Market - Clinical Pipeline by Mechanism of Action, 2010
  • Figure 9: Acute Coronary Syndrome Market - Clinical Pipeline by Phase of Development, 2010
  • Figure 10: Implications for Future Market Competition in the Acute Coronary Syndrome Market, 2010
  • Figure 11: Acute Coronary Syndrome Market - Clinical Pipeline by Company, 2010
  • Figure 12: GlobalData Methodology
  • Figure 13: GlobalData Market Forecasting Model